Stockreport

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF REDWOOD CITY, Calif., December 06, 2025 BUSINESS WIRE )--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innova [Read more]